IPO Guru

IPO Listed — 05 Aug 2026

Listing Price: ₹652

vs Issue Price ₹590 +₹62 (+10.51%)

Manipal Health Enterprises IPO GMP History | Listing Price ₹652 & Kostak Rate

IPO
Final GMP
₹ 3
0.51%
Final Kostak
₹ 0
Final Sub. to Sauda
₹ 0

Manipal Health Enterprises IPO has been listed on August 5, 2026 at a listing price of ₹652, against the issue price of ₹590 — a gain of ₹62 (+10.51%). The GMP peaked at ₹35 on 24 July 2026 and reached a low of ₹-15 on 1 August 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.

Manipal Health Enterprises IPO raised ₹9275.22 Cr. through its IPO at a price band of ₹560 to ₹590 per share, with a lot size of 25 shares. The IPO was open for subscription from 29 Jul 2026 to 31 Jul 2026.

GMP Trend Chart

Day-wise GMP Trend

Date GMP ↑↓ % Kostak Sub. Sauda
05 Aug 2026 ₹ 3 0.51% ₹ 0 ₹ 0
04 Aug 2026 ₹ 3 0.51% ₹ 0 ₹ 0
03 Aug 2026 ₹ -6 -1.02% ₹ 0 ₹ 0
01 Aug 2026 ₹ -15 -2.5% ₹ 0 ₹ 0
31 Jul 2026 ₹ -15 -2.5% ₹ 0 ₹ 0
30 Jul 2026 ₹ 6 1.0% ₹ 0 ₹ 0
29 Jul 2026 ₹ 9 1.5% ₹ 0 ₹ 0
28 Jul 2026 ₹ 9.5 1.6% ₹ 0 ₹ 0
27 Jul 2026 ₹ 13 2.2% ₹ 0 ₹ 0
26 Jul 2026 ₹ 25 4.2% ₹ 0 ₹ 0
25 Jul 2026 ₹ 25 4.2% ₹ 0 ₹ 0
24 Jul 2026 ₹ 35 5.9% ₹ 0 ₹ 0

Manipal Health Enterprises IPO Dates

Event Date
Open Date 29 Jul, 2026
Close Date 31 Jul, 2026
Allotment Date 03 Aug, 2026
Refund Date 04 Aug, 2026
Credit to Demat 04 Aug, 2026
Listing Date 05 Aug, 2026

Manipal Health Enterprises IPO Actual Listing Price

Basis Value
Issue Price ₹590
GMP-Based Estimate (Pre-Listing) ₹593 (+0.5%)
Actual Listing Price ₹652 (+10.51%)
Listing Gain / Loss +₹62 per share
Listing Date 05 Aug, 2026

Is Manipal Health Enterprises IPO GMP Reliable?

Grey market premium for Manipal Health Enterprises IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:

  • Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
  • Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
  • Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
  • Cross-check before acting: Review the Manipal Health Enterprises IPO full review for a fundamentals-based assessment before making any grey market trades.

Manipal Health Enterprises IPO IPO Kostak Rate Explained

The Kostak rate for Manipal Health Enterprises IPO was not active during the subscription period, as no grey market premium was established. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.

The Subject to Sauda price was not active for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.

Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.

About Manipal Health Enterprises IPO

Incorporated in 2010, Manipal Health Enterprises Limited is a healthcare service provider operating a large network of multi-specialty hospitals, clinics and diagnostic centres across the country. It is part of the Manipal Group, founded by T. M. A. Pai. The company offers a wide range of healthcare services including tertiary and quaternary care, organ transplants, oncology, cardiology, neurology, orthopaedics and preventive healthcare. Its hospitals are equipped with advanced medical technology and are staffed by experienced medical professionals.

Manipal Health focuses on delivering quality, patient-centric care and expanding access to healthcare through strategic acquisitions, partnerships and continuous investment in medical infrastructure and digital health initiatives. As of March 31, 2026, the company operated 49 hospitals with 13,037 licensed beds across 14 states and union territories, along with 21 clinics.

As of March 31, 2026, the company had 24,240 full-time employees across its hospitals and corporate functions, comprising 11,048 nurses, 6,362 paramedics and 6,830 administrative employees.

Strengths & Risks

Strengths

  • India's largest multi-specialty hospital group by bed capacity, with a pan-India presence and leadership in its three key regions.
  • The only private hospital chain network in India with leadership in three metros (Bengaluru, Kolkata and Pune), with a balanced and diversified presence across metros and non-metros.
  • Widely recognised brand and network of choice for patients, doctors and healthcare professionals.
  • Advanced infrastructure and medical equipment, with a strong focus on clinical excellence.
  • Track record of industry-leading growth with strong profitability and efficiency metrics, with FY26 ROCE of 21.88% and EBITDA margin of 27.05%.

Risks

  • Valuation is rich - the issue is priced at about 85 times post-issue FY26 earnings, against a listed peer average of about 70 times.
  • Profit after tax fell about 15% in FY26 to Rs 916.52 crore even as revenue grew about 25%, on higher employee, finance and depreciation costs.
  • Total borrowings more than doubled to Rs 10,553.43 crore in FY26 and net debt to adjusted EBITDA rose to 3.74x from 2.00x.
  • Around Rs 1,275.22 crore of the issue is an Offer for Sale, and those proceeds go to the selling shareholders, not to the company.
  • Growth has relied on acquisitions such as Sahyadri Hospitals, carrying integration, goodwill and execution risk.
  • Healthcare is a highly regulated sector, subject to clinical, accreditation and price-regulation risks.

Frequently Asked Questions about Manipal Health Enterprises IPO

What is the GMP of Manipal Health Enterprises IPO?

The current Grey Market Premium (GMP) of Manipal Health Enterprises IPO is ₹ 3.

What is the Kostak Price of Manipal Health Enterprises IPO?

Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Manipal Health Enterprises IPO is currently not available.

What is the Subject to Sauda Price of Manipal Health Enterprises IPO?

Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is currently not available.

What was the actual listing price of Manipal Health Enterprises IPO?

Manipal Health Enterprises IPO listed on August 5, 2026 at ₹652, against the issue price of ₹590 — a gain of +10.51%.

How did the GMP of Manipal Health Enterprises IPO trend before listing?

The GMP of Manipal Health Enterprises IPO was stable in its final days before listing. The GMP peaked at ₹35 on 24 July 2026. View the day-wise table above for the complete GMP history.

Explore Manipal Health Enterprises IPO Further

For a complete picture before making your investment decision, explore these resources:

Discussion 0

💡
Commenting as
Markdown supported: **bold**, _italics_

No comments yet

Be the first to share your thoughts!

Advertisement